A detailed history of Royal Bank Of Canada transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 4,573 shares of TSVT stock, worth $13,673. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,573
Previous 4,598 0.54%
Holding current value
$13,673
Previous $17,000 23.53%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.85 - $5.05 $96 - $126
-25 Reduced 0.54%
4,573 $21,000
Q2 2024

Aug 14, 2024

BUY
$3.6 - $5.79 $12,427 - $19,987
3,452 Added 301.22%
4,598 $17,000
Q1 2024

Nov 05, 2024

SELL
$3.09 - $6.0 $10,666 - $20,712
-3,452 Reduced 75.08%
1,146 $6,000
Q1 2024

May 15, 2024

SELL
$3.09 - $6.0 $51,392 - $99,792
-16,632 Reduced 93.55%
1,146 $6,000
Q4 2023

Feb 14, 2024

BUY
$1.57 - $4.58 $11,657 - $34,006
7,425 Added 71.72%
17,778 $75,000
Q3 2023

Nov 14, 2023

BUY
$3.14 - $11.2 $10,063 - $35,896
3,205 Added 44.84%
10,353 $40,000
Q2 2023

Aug 14, 2023

BUY
$8.45 - $12.48 $26,389 - $38,975
3,123 Added 77.59%
7,148 $72,000
Q1 2023

May 15, 2023

SELL
$9.21 - $14.98 $19,654 - $31,967
-2,134 Reduced 34.65%
4,025 $41,000
Q4 2022

Feb 14, 2023

BUY
$8.57 - $17.0 $14,817 - $29,393
1,729 Added 39.03%
6,159 $57,000
Q3 2022

Nov 14, 2022

BUY
$12.56 - $17.54 $11,429 - $15,961
910 Added 25.85%
4,430 $66,000
Q2 2022

Aug 15, 2022

SELL
$10.55 - $18.81 $14,611 - $26,051
-1,385 Reduced 28.24%
3,520 $46,000
Q1 2022

May 16, 2022

SELL
$11.67 - $26.72 $34,939 - $79,999
-2,994 Reduced 37.9%
4,905 $84,000
Q4 2021

Feb 14, 2022

BUY
$13.77 - $42.56 $108,769 - $336,181
7,899 New
7,899 $203,000

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $113M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.